Glass House Brands (GLAS) Asset Writedowns and Impairment (2022 - 2026)
Glass House Brands (GLAS) posted quarterly Asset Writedowns and Impairment of -$128000.0 for Q1 2026, up 76.68% quarter-over-quarter from -$549000.0 in Q4 2025.
Glass House Brands (GLAS) Asset Writedowns and Impairment (2022 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Asset Writedowns and Impairment for 5 consecutive years, with -$128000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to -$128000.0; the TTM figure through Mar 2026 stood at -$522000.0 (changed N/A YoY), while the FY2025 annual figure was $1.4 million, down 78.56% from the prior year.
- Asset Writedowns and Impairment improved to -$128000.0 in Q1 2026 per GLAS's latest filing, from -$549000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1328.4 billion in Q2 2023 and bottomed at -$549000.0 in Q4 2025.
- Historically, Asset Writedowns and Impairment has averaged $132.8 billion across 5 years, with a median of $157541.0 in 2022.
- Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment soared 436751488.8% — and 2024, when it plunged 100.18%.
- Glass House Brands' Asset Writedowns and Impairment stood at $817875.0 in 2022, then soared by 162424231.35% to $1328.4 billion in 2023, then plunged by 100.0% to $155000.0 in 2024, then slumped by 454.19% to -$549000.0 in 2025, then surged by 76.68% to -$128000.0 in 2026.
- Business Quant data shows GLAS's Asset Writedowns and Impairment at -$128000.0 in Q1 2026, -$549000.0 in Q4 2025, and $155000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Glass House Brands | 837.25 Mn | 818.69 Mn | 15.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128,000.00 |
| Mar 31, 2026 | -128,000.00 |
| Dec 31, 2025 | -549,000.00 |
| Dec 31, 2025 | -549,000.00 |
| Jun 30, 2024 | 155,000.00 |
| Jun 30, 2024 | 155,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Jun 30, 2023 | 1,328.43 Bn |
| Jun 30, 2023 | 1,328.43 Bn |
| Mar 31, 2023 | 5.53 Mn |
| Mar 31, 2023 | 5.53 Mn |
| Dec 31, 2022 | 817,875.00 |
| Dec 31, 2022 | 817,875.00 |
| Sep 30, 2022 | 160,082.00 |
| Sep 30, 2022 | 160,082.00 |
| Jun 30, 2022 | 304,161.00 |
| Jun 30, 2022 | 304,161.00 |
| Mar 31, 2022 | 80,110.00 |
| Mar 31, 2022 | 80,110.00 |